Want to see NVZMY full AI Analyst Report?
Novonesis (NVZMY) AI Stock Analysis
Top Page
Novonesis
(Other OTC:NVZMY)
The score is driven primarily by solid operating performance and strong cash generation, supported by constructive technical momentum and a generally positive earnings update with raised guidance and capital returns. These positives are tempered by earnings volatility (including a TTM net loss), balance-sheet inconsistency in leverage readings, and a relatively expensive valuation (high P/E and low yield).
Novonesis (NVZMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $32.19B
- Dividend Yield
- 0.23%
- Average Volume (3M)
- 25.42K
- Price to Earnings (P/E)
- 44.2
- Beta (1Y)
- 0.07
- Revenue Growth
- 12.46%
- EPS Growth
- 19.92%
- Country
- US
- Employees
- 11,641
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Novonesis Business Overview & Revenue Model
Company Description
Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America...
How the Company Makes Money
Novonesis makes money primarily by selling bio-based ingredients and solutions—most notably enzymes and microbial cultures/biocultures—to business customers (B2B) worldwide. Revenue is generated through commercial supply agreements where customers pu...
Novonesis Earnings Call Summary
The call presented strong, broad-based organic growth, margin expansion, robust cash generation and clear capital allocation actions (EUR 1bn buyback, bolt‑on M&A, capacity investments). These positives were balanced by notable headwinds — currency effects, country exits, a softer Human Health outlook, one-off inventory timing and a temporary elevation in CapEx and operating costs. On balance the company appears to be executing well and is confident in sustainable demand and returns, but investors should monitor H2 effects from tariff reimbursements, the normalization of the Q1 inventory benefit and the near-term impact of elevated CapEx.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novonesis raised its 2026 organic sales guidance to 7–8%, expecting growth to be mainly volume-driven and supported by roughly 1 percentage point each from pricing and sales synergies while including close to a 1 pp drag from exiting certain countries; the outlook also factors a minor H2 headwind from U.S. tariff reimbursements (up to ~40 bps), a softer Human Health H2 and high Q3 comparables. Management now expects adjusted EBITDA margin at the higher end of the 37–38% range (~38%) and net debt/EBITDA of ~1.8x at year‑end, with 2026 CapEx stepped up to 12–14% of sales (normalizing to high single‑digits by 2030). They announced a EUR 1bn buyback through 2029, an interim dividend of DKK 2.35, and reiterated the target to double adjusted ROIC (ex‑goodwill) to 16% by 2030; H1 metrics included operating cash flow EUR 523.3m, free cash flow before acquisitions EUR 307.6m and adjusted EPS (ex PPA) EUR 1.09 (+9% y/y).
Novonesis Financial Statement Overview
Summary
Strong operating profile and cash generation (TTM revenue growth ~30%, healthy gross/EBIT margins, and sharply higher free cash flow), but the TTM net loss and volatility in profitability plus a notable leverage swing (2025 debt-to-equity ~2.07 vs. more conservative TTM) reduce confidence in earnings quality and balance-sheet consistency.
Income Statement
58NeutralBalance Sheet
46NeutralCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.31B | 4.16B | 513.65M | 17.90B | 17.55B | 14.95B |
| Gross Profit | 2.37B | 2.24B | 242.45M | 9.72B | 9.58B | 8.62B |
| EBITDA | 1.53B | 1.39B | 1.21B | 5.47B | 6.12B | 5.39B |
| Net Income | -253.80M | 583.60M | 40.97M | 3.02B | 3.68B | 3.15B |
Balance Sheet | ||||||
| Total Assets | 16.63B | 16.35B | 15.20B | 28.39B | 27.98B | 24.77B |
| Cash, Cash Equivalents and Short-Term Investments | 313.47M | 295.60M | 284.00M | 1.16B | 1.11B | 1.04B |
| Total Debt | 3.07B | 22.45B | 1.80B | 7.73B | 6.95B | 482.00M |
| Total Liabilities | 5.48B | 5.49B | 4.02B | 14.04B | 13.76B | 12.56B |
| Stockholders Equity | 11.15B | 10.86B | 11.18B | 13.98B | 13.84B | 11.83B |
Cash Flow | ||||||
| Free Cash Flow | 3.20B | 750.70M | 660.10M | 2.10B | 1.12B | 2.82B |
| Operating Cash Flow | 4.32B | 1.22B | 1.02B | 4.15B | 4.01B | 4.06B |
| Investing Cash Flow | -2.09B | -1.97B | -199.70M | -2.13B | -2.67B | -2.75B |
| Financing Cash Flow | -2.55B | 753.30M | -703.20M | -1.89B | -1.25B | -1.59B |
Novonesis Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVZMY, the sentiment is Positive. The current price of 69.01 is above the 20-day moving average (MA) of 67.94, above the 50-day MA of 67.62, and above the 200-day MA of 62.29, indicating a bullish trend. The MACD of 1.07 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 10.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVZMY.
Novonesis Peers Comparison
Overall Rating
SHW69Neutral
EMN65Neutral
ESI62Neutral
PPG62Neutral- NVZMY62Neutral
SCL61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SHW | 69Neutral | $80.35B | 30.29 | 63.49% | 0.96% | 7.03% | 5.95% |
| EMN | 65Neutral | $7.61B | 11.73 | 10.63% | 5.05% | 0.40% | -6.58% |
| ESI | 62Neutral | $8.31B | 40.55 | 7.39% | 0.93% | 39.62% | -14.83% |
| PPG | 62Neutral | $26.40B | 16.98 | 19.05% | 2.40% | 6.39% | 27.29% |
| NVZMY | 62Neutral | $32.16B | 44.16 | 5.79% | 0.23% | 12.46% | 19.92% |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| SCL | 61Neutral | $1.58B | 366.37 | 0.36% | 2.27% | 10.02% | -90.50% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVZMY | Novonesis A/S - Adr | 69.01 | 9.80 | 16.56% | |
| EMN | Eastman Chemical Company | 66.53 | 11.40 | 20.67% | |
| PPG | Ppg Industries, Inc. | 119.52 | 26.98 | 29.16% | |
| SHW | Sherwin-Williams | 332.61 | -9.78 | -2.86% | |
| SCL | Stepan Company | 69.61 | 28.35 | 68.72% | |
| ESI | Element Solutions | 34.27 | 7.41 | 27.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026